Clinical Trial Update: Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS [Phase 1]

View source ↗

Summary

A Phase 1 trial of magrolimab in combination with azacitidine after allogeneic hematopoietic cell transplantation in high-risk acute myeloid leukemia or myelody…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Magrolimab (magrolimab)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: WITHDRAWN